Expression and clinical significance of serum chemokines in patients with lung cancer

Abstract

Abstract: 【Abstract】ObjectiveTo detect the expression levels of multiple serum chemokines including IFNinducible T cell chemoattractant (ITAC), Fractalkine, macrophage inflammatory protein(MIP)3α, IL8, MIP1α, MIP1β in patients with lung cancer and explore their association with the clinical characteristics of lung cancer as well as the correlations among these chemokines. MethodsForty newly diagnosed patients with lung cancer and thirty healthy controls were enrolled for detection of the serum levels of 6 kinds of chemokines by Luminex technology. The correlations of clinical characteristics of lung cancer with these chemokines and the correlations among these chemokines were analyzed by SPSS 17.0 software. ResultsThe serum levels ［M(QR)］ of IL8, Fractalkine and MIP3α in patients with lung cancer were 5.16（4.74）, 128.45(141.89), 10.31(8.88) respectively, and 2.01（0.95）, 61.46(74.81), 8.08(5.87) respectively in control group, with significant differences (Z=-4.783, P＜0.001; Z=-4.046, P＜0.001; Z=-3.105, P=0.002). The expression of MIP1β in lung adenocarcinoma was significantly higher than that in squamous carcinoma ［18.32(12.27) vs. 13.72(7.31), Z=-2.212, P=0.027］, and of ITAC in squamous carcinoma was significantly higher than that in small cell lung cancer ［24.51(22.48) vs. 9.28(4.85), Z=-2.460, P=0.014］. The expressions of MIP3α and Fractalkine were positively correlated in the two groups (r=0.619, P＜0.001; r=0.766, P＜0.001). ConclusionThe expressions of IL8, Fractalkine and MIP3α increase significantly in lung cancer patients, and they are may play important roles in metastatic lung cancer.

Key words: Lung neoplasms, Chemotactic factors, Receptors, chemokine

WANG Wan-Wan, SUN Jun-Ning, CAO Zhen, LI Hai-Yan, SU Wen. Expression and clinical significance of serum chemokines in patients with lung cancer[J]. Journal of International Oncology, 2016, 43(2): 90-.

References

［1］ Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012［J］. CA Cancer J Clin, 2015, 65(2): 87108. DOI:10.3322/caac.21262. ［2］ Luppi F, Longo AM, De Boer WI, et al. Interleukin8 stimulates cell proliferation in nonsmall cell lung cancer through epidermal growth factor receptor transactivation［J］. Lung Cancer, 2006, 56(1): 2533. ［3］ Zhu YM, Webster SJ, Flower D, et al. Interleukin8/CXCL8 is a growth factor for human lung cancer cells［J］. Br J Cancer, 2004, 91(11): 19701976. ［4］ Sanmamed MF, CarranzaRua O, Alfaro C, et al. Serum interleukin8 reflects tumor burden and treatment response across malignancies of multiple tissue origins［J］. Clin Cancer Res, 2014, 20(22): 56975707. DOI:10.1158/10780432.CCR133203. ［5］ Song XY, Zhou SJ, Xiao N, et al. Research on the relationship between serum levels of inflammatory cytokines and nonsmall cell lung cancer［J］. Asian Pac J Cancer Prev, 2013, 14(8): 47654768. ［6］ Liu Z, Xu S, Xiao N, et al. Overexpression of IL8 and MMP9 confer high malignant phenotype in patients with nonsmall cell lung cancer［J］. Zhongguo Fei Ai Za Zhi, 2010, 13(8): 795802. DOI:10.3779/j.issn.10093419.2010.08.09. ［7］ Lee LF, Hellendall RP, Wang Y, et al. IL8 reduced tumorigenicity of human ovarian cancer in vivo due to neutrophil infiltration［J］. J Immunol, 2000, 164(5): 27692775. ［8］ Park MH, Lee JS, Yoon JH. High expression of CX3CL1 by tumor cells correlates with a good prognosis and increased tumorinfiltrating CD8+ T cells, natural killer cells, and dendritic cells in breast carcinoma［J］. J Surg Oncol, 2012, 106(4): 386392. DOI:10.1002/jso.23095. ［9］ Ohta M, Tanaka F, Yamaguchi H, et al. The high expression of Fractalkine results in a better prognosis for colorectal cancer patients［J］. Int J Oncol, 2005, 26(1): 4147. ［10］ Hyakudomi M, Matsubara T, Hyakudomi RA, et al. Increased expression of Fractalkine is correlated with a better prognosis and an increased number of both CD8(+) T cells and natural killer cells in gastric adenocarcinoma［J］. Ann Surg Oncol, 2008, 15(6): 17751782. DOI:10.1245/s1043400898763. ［11］ Jy K, Arita Y, Shinohara K, et al. Antitumor immune activity by chemokine CX3CL1 in an orthotopic implantation of lung cancer model in vivo［J］. Mol Clin Oncol, 2013, 1(1): 3540. ［12］Ren T, Chen QF, Tian ZG, et al. Downregulation of surface fractalkine by RNA interference in B16 melanoma reduced tumor growth in mice［J］. Biochem Biophys Res Commun, 2007, 364(4): 978984. DOI:10.1016/j.bbrc.2007.10.124. ［13］Kirshberg S, Izhar U, Amir G, et al. Involvement of CCR6/CCL20/IL17 axis in NSCLC disease progression［J］. PLoS One, 2011, 6(9): e24856. DOI:10.1371/journal.pone.0024856. ［14］Yamauchi K, Akbar SM, Horiike N, et al. Increased serum levels of macrophage inflammatory protein3 alpha in hepatocellular carcinoma: Relationship with clinical factors and prognostic importance during therapy［J］. Int J Mol Med, 2003, 11(5): 601605. ［15］Cai Y, Li J, Lu A, et al. Increased serum levels of macrophage inflammatory protein3α and cystatin a predict a poor prognosis of nasopharyngeal carcinoma［J］. Medicine (Baltimore), 2014, 93(22): e123. DOI:10.1097/MD.0000000000000123. ［16］Iwata T, Tanaka K, Inoue Y, et al. Macrophage inflammatory protein3 alpha (MIP3a) is a novel serum prognostic marker in patients with colorectal cancer［J］. J Surg Oncol, 2013, 107(2): 160166. DOI:10.1002/jso.23247. ［17］Zhang XP, Meng AH, Wang HE, et al. High serum macrophage inflammatory protein3α is associated with the early recurrence or metastasis of nonsmall cell lung cancer following primary pulmonary resection［J］. Oncol Lett, 2014, 8(2): 948952. DOI:10.3892/ol.2014.2229. ［18］Kanegasaki S, Tsuchiya T. Alarmins released during local antitumor treatments play an essential role in enhancing tumor growth inhibition at treated and nontreated sites via a derivative of CCL3［J］. Oncoimmunology, 2014, 3(10): e958956. ［19］He S, Wang L, Wu Y, et al. CCL3 and CCL20recruited dendritic cells modified by melanoma antigen gene1 induce antitumor immunity against gastric cancer ex vivo and in vivo［J］. J Exp Clin Cancer Res, 2010, 29(1): 37. DOI:10.1186/175699662937. ［20］Luo X, Yu Y, Liang A, et al. Intratumoral expression of MIP1beta induces antitumor responses in a preestablished tumor model throughchemoattracting T cells and NK cells［J］. Cell Mol Immunol, 2004, 1(3): 199204. ［21］Sadeghi M, Lahdou I, Oweira H, et al. Serum levels of chemokines CCL4 and CCL5 in cirrhotic patients indicate the presence of hepatocellularcarcinoma［J］. Br J Cancer, 2015, 113(5): 756762. DOI:10.1038/bjc.2015.227. ［22］Chu Y, Yang X, Xu W, et al. In situ expression of IFNgammainducible T cell alpha chemoattractant in breast cancer mounts an enhanced specific antitumor immunity which leads to tumor regression［J］. Cancer Immunol Immunother, 2007, 56(10): 15391549. DOI:10.1007/s0026200702961.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	He Jiahui, Hu Qinyong. Comparative analysis of lung cancer incidence and mortality trends and risk factors in China and the United States based on GBD data [J]. Journal of International Oncology, 2024, 51(1): 29-36.
[3]	Zuo Xiaoping, Liu Xiaochuan, Wu Xiqiang, Li Zhou, Xia Tian, Liu Guofeng. Risk factors and prediction model construction of arrhythmia in elderly patients with early lung cancer after thoracoscopic pulmonary resection [J]. Journal of International Oncology, 2023, 50(12): 711-716.
[4]	Chen Yu, Xu Hua, Liu Hai, Chen Shixin. Construction of pathological classification prediction model for malignant pulmonary pure ground-glass nodule patients based on CT imaging [J]. Journal of International Oncology, 2023, 50(11): 655-660.
[5]	Yang Sha, Yang Xiaohua, Wang Suhua, Xue Xiaoyan, Xu Jun. Analysis of risk factors for deep vein thrombosis of lower extremity after thoracoscopic surgery for elderly lung cancer and establishment and validation of prediction model [J]. Journal of International Oncology, 2022, 49(9): 532-536.
[6]	Chen Huangjing, Zhu Pengfei, Zhang Qing, Chen Guifang, Yang Chunlin, He Ying. Comparative study on the clinical value of contrast-enhanced ultrasound- and CT-guided percutaneous puncture biopsy in peripheral lung masses [J]. Journal of International Oncology, 2022, 49(8): 459-463.
[7]	Cai Gangxiang, Li Jing, Xu Bin. Advances in neoadjuvant immunotherapy for lung cancer [J]. Journal of International Oncology, 2022, 49(6): 366-370.
[8]	Zhang Jingxian, Yi Dan, Li Xiaojiang. Application of antibody-drug conjugates in the treatment of non-small cell lung cancer [J]. Journal of International Oncology, 2022, 49(5): 296-301.
[9]	Gao Min, Feng Jing, Wang Li, Zhong Hai, Wen Yuting, Wan Bing, Zhang Xiuwei. Application of microbiota in the early diagnosis and adjunctive treatment of lung cancer [J]. Journal of International Oncology, 2022, 49(4): 247-251.
[10]	Gao Shile, Lu Donghui, Liu Meiqin, Xu Xingjun, Ma Huan, Zhang Yu. Clinical efficacy and optimal dose of apatinib combined with chemotherapy in patients with advanced non-small cell lung cancer [J]. Journal of International Oncology, 2022, 49(3): 140-145.
[11]	Xie Hongxia, Zuo Jinhui, Liao Dongying, Deng Renfen, Yao Yang, Jia Yingjie, Li Xiaojiang, Kong Fanming. Application of PD-L1 inhibitors in the treatment of non-small cell lung cancer [J]. Journal of International Oncology, 2022, 49(2): 111-115.
[12]	Huang Huayu, Song Qibin, Gong Hongyun, Song Jia. Analysis on the incidence and risk factors of pneumonia in patients with lung cancer receiving thoracic radiotherapy and immunotherapy [J]. Journal of International Oncology, 2022, 49(12): 718-723.
[13]	Zhang Hongjiao, Jiang Jie, Huang Wei. Research progress of functional imaging-assisted radiotherapy target delineation of lung cancer with atelectasis [J]. Journal of International Oncology, 2022, 49(1): 51-55.
[14]	Hu Ge, Su Jie, Li Qiangwei, Xu Peng, Xu Xiuli, Qian Xiaotao. Value of CD4/CD8 ratio and total B lymphocytes before radiotherapy in predicting radiation pneumonitis in patients with esophageal cancer and lung cancer [J]. Journal of International Oncology, 2021, 48(9): 523-526.
[15]	Wang Jun, Zhao Xia, Li Haifei, Zhang Cheng. Clinic diagnostic value of MSCT imaging features in nodular lung adenocarcinoma subtype [J]. Journal of International Oncology, 2021, 48(9): 537-543.